In an open-label extension spanning 5 years, the safety profile of erenumab was consistent with the double-blind treatment phase of the study, and there were no increases in adverse event rates.
Results from the 5-year, open-label treatment period of a phase 2 study in episodic migraine prevention showed that erenumab (Aimovig) helped patients achieve sustained reductions in both the number of monthly migraine days (MMD) and the number of days in which therapies were needed for acute migraines.
Amgen and Novartis released the results during the Migraine Trust Virtual Symposium. Erenumab, the first-of-its-kind calcitonin gene-related peptide (CGRP) inhibitor, was approved for sale in the United States and the European Union in 2018. Its safety profile was consistent with the double-blind treatment phase of the study, and there were no increases in adverse event rates over the 5 years.
The 5-year open label extension enrolled 383 patients with episodic migraine who had previously completed the 12-week, double-blind, placebo-controlled trial. Episodic migraine was defined as 4 to 14 migraine days and less than 15 headache days per month.
Results from the extension period were compared with the baseline seen in the double-blind portion. All patients initially received 70-mg erenumab monthly, with 250 patients increasing their dosage to 140 mg monthly.
Among the 216 patients who completed the open-label treatment phase, there was an average MMD reduction of 5.3 days from the baseline of 8.7 days.
By the end of the study, patients who had used acute migraine therapies to treat their migraines saw an average reduction in use of 4.4 days from a baseline of 6.2 days with erenumab.
The most common adverse effects were nasopharyngitis, upper respiratory tract infection, and influenza.
"These important data highlight the sustained efficacy, safety, and tolerability profile of Aimovig, and provide crucial information for patients and doctors managing migraine," said Messoud Ashina, MD, PhD, professor of neurology in the Faculty of Health and Medical Sciences at the University of Copenhagen. "The study reinforces the potential of Aimovig to reduce monthly migraine days over the long term for people living with this debilitating, yet underdiagnosed disease.”
"Aimovig continues to have the longest safety and efficacy trial data among treatments for migraine in the calcitonin gene-related peptide class of medications," said Darryl Sleep, MD, senior vice president, Global Medical, and chief medical officer at Amgen. "These long-term results further demonstrate the potential of Aimovig to help the millions of patients who may be candidates for preventive treatment."
The companies also released interim 2-year results of the open-label extension of the LIBERTY study, which involved patients with episodic migraine taking erenumab who failed 2 to 4 prior preventive treatments. As with the other results, there was sustained efficacy and no increases in adverse events rates.
The phase 3 EMPOwER study results, which highlighted the efficacy and safety of erenumab in adult patients with episodic migraine from Asia, the Middle East and Latin America, were also released.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More